Ada Rephaeli

3.1k total citations
88 papers, 2.7k citations indexed

About

Ada Rephaeli is a scholar working on Molecular Biology, Oncology and Organic Chemistry. According to data from OpenAlex, Ada Rephaeli has authored 88 papers receiving a total of 2.7k indexed citations (citations by other indexed papers that have themselves been cited), including 74 papers in Molecular Biology, 24 papers in Oncology and 10 papers in Organic Chemistry. Recurrent topics in Ada Rephaeli's work include Histone Deacetylase Inhibitors Research (29 papers), Cancer therapeutics and mechanisms (17 papers) and Retinoids in leukemia and cellular processes (10 papers). Ada Rephaeli is often cited by papers focused on Histone Deacetylase Inhibitors Research (29 papers), Cancer therapeutics and mechanisms (17 papers) and Retinoids in leukemia and cellular processes (10 papers). Ada Rephaeli collaborates with scholars based in Israel, Australia and United States. Ada Rephaeli's co-authors include Abraham Nudelman, Suzanne M. Cutts, Don R. Phillips, Lonnie P. Swift, Milton H. Saier, Nataly Tarasenko, Mati Shaklai, Steven J.D. Karlish, Michal Entin‐Meer and Donald E. Richards and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Blood.

In The Last Decade

Ada Rephaeli

88 papers receiving 2.6k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ada Rephaeli Israel	33	1.8k	564	300	269	265	88	2.7k
Suzanne M. Cutts Australia	29	1.7k 0.9×	663 1.2×	350 1.2×	357 1.3×	254 1.0×	77	2.7k
Howard R. Mellor United Kingdom	26	1.3k 0.7×	862 1.5×	187 0.6×	451 1.7×	219 0.8×	35	2.8k
Stuart J. Conway United Kingdom	34	2.8k 1.5×	307 0.5×	343 1.1×	536 2.0×	206 0.8×	109	4.2k
Rebecca Cowling United States	19	2.1k 1.1×	328 0.6×	110 0.4×	252 0.9×	215 0.8×	29	2.9k
Ebbe Boedtkjer Denmark	28	1.7k 0.9×	363 0.6×	256 0.9×	119 0.4×	427 1.6×	73	2.9k
J. Oliver McIntyre United States	27	1.1k 0.6×	343 0.6×	103 0.3×	124 0.5×	242 0.9×	68	2.2k
Masato Sasaki Japan	28	1.6k 0.9×	378 0.7×	113 0.4×	634 2.4×	131 0.5×	113	3.4k
Cynthia Hong United States	39	2.2k 1.2×	682 1.2×	243 0.8×	807 3.0×	81 0.3×	56	5.6k
Claus Olesen Denmark	22	1.9k 1.0×	228 0.4×	219 0.7×	90 0.3×	141 0.5×	45	2.4k
Hyunseung Lee South Korea	31	1.1k 0.6×	372 0.7×	81 0.3×	431 1.6×	404 1.5×	107	2.5k

Countries citing papers authored by Ada Rephaeli

Since Specialization

Citations

This map shows the geographic impact of Ada Rephaeli's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ada Rephaeli with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ada Rephaeli more than expected).

Fields of papers citing papers by Ada Rephaeli

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ada Rephaeli. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ada Rephaeli. The network helps show where Ada Rephaeli may publish in the future.

Co-authorship network of co-authors of Ada Rephaeli

This figure shows the co-authorship network connecting the top 25 collaborators of Ada Rephaeli. A scholar is included among the top collaborators of Ada Rephaeli based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ada Rephaeli. Ada Rephaeli is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Nudelman, Abraham, et al.. (2022). An evaluation of the interaction of pixantrone with formaldehyde-releasing drugs in cancer cells. Cancer Chemotherapy and Pharmacology. 89(6). 773–784. 2 indexed citations

McGrath, Sean, Alex Spurling, Peter Lock, et al.. (2021). A switch in mechanism of action prevents doxorubicin-mediated cardiac damage. Biochemical Pharmacology. 185. 114410–114410. 7 indexed citations

Nudelman, Vadim, Muayad A. Zahalka, Abraham Nudelman, Ada Rephaeli, & Gania Kessler‐Icekson. (2020). Cardioprotection by AN-7, a prodrug of the histone deacetylase inhibitor butyric acid: Selective activity in hypoxic cardiomyocytes and cardiofibroblasts. European Journal of Pharmacology. 882. 173255–173255. 8 indexed citations

Zhu, Xingguo, Yaqin Li, Kenneth R. Peterson, et al.. (2019). Conjugate prodrug AN-233 induces fetal hemoglobin expression in sickle erythroid progenitors and β-YAC transgenic mice. Blood Cells Molecules and Diseases. 79. 102345–102345. 9 indexed citations

Bahar, Irit, Ada Rephaeli, Abraham Nudelman, et al.. (2017). Effect of Histone Deacetylase Inhibitor, Butyroyloxymethyl-Diethyl Phosphate (AN-7), on Corneal Neovascularization in a Mouse Model. Journal of Ocular Pharmacology and Therapeutics. 33(6). 480–486. 8 indexed citations

Tarasenko, Nataly, et al.. (2017). Effects of histone deacetylase inhibitory prodrugs on epigenetic changes and DNA damage response in tumor and heart of glioblastoma xenograft. Investigational New Drugs. 35(4). 412–426. 10 indexed citations

Cutts, Suzanne M., et al.. (2015). Potential Therapeutic Advantages of Doxorubicin when Activated by Formaldehyde to Function as a DNA Adduct-Forming Agent. Current Topics in Medicinal Chemistry. 15(14). 1409–1422. 19 indexed citations

Swift, Lonnie P., Ada Rephaeli, Abraham Nudelman, et al.. (2012). Activation of DNA damage response pathways as a consequence of anthracycline-DNA adduct formation. Biochemical Pharmacology. 83(12). 1602–1612. 62 indexed citations

Tarasenko, Nataly, Gania Kessler‐Icekson, P. Boer, et al.. (2010). The histone deacetylase inhibitor butyroyloxymethyl diethylphosphate (AN-7) protects normal cells against toxicity of anticancer agents while augmenting their anticancer activity. Investigational New Drugs. 30(1). 130–143. 33 indexed citations

10.

Nudelman, Abraham, et al.. (2009). Development of Pluronic Micelle-Encapsulated Doxorubicin and Formaldehyde-Releasing Prodrugs for Localized Anticancer Chemotherapy. Oncology Research Featuring Preclinical and Clinical Cancer Therapeutics. 17(7). 283–299. 13 indexed citations

11.

Bareket, Lilach, et al.. (2009). Carbon nanotubes based electrochemical biosensor for detection of formaldehyde released from a cancer cell line treated with formaldehyde-releasing anticancer prodrugs. Bioelectrochemistry. 77(2). 94–99. 39 indexed citations

12.

Tarasenko, Nataly, et al.. (2007). The anticancer prodrugs of butyric acid AN-7 and AN-9, possess antiangiogenic properties. Cancer Letters. 256(1). 39–48. 31 indexed citations

13.

Entin‐Meer, Michal, Xiaodong Yang, Scott R. VandenBerg, et al.. (2007). In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas1. Neuro-Oncology. 9(2). 82–88. 45 indexed citations

14.

Swift, Lonnie P., et al.. (2007). The cardio-protecting agent and topoisomerase II catalytic inhibitor sobuzoxane enhances doxorubicin-DNA adduct mediated cytotoxicity. Cancer Chemotherapy and Pharmacology. 61(5). 739–749. 32 indexed citations

15.

Entin‐Meer, Michal, et al.. (2007). AN-113, a novel prodrug of 4-phenylbutyrate with increased anti-neoplastic activity in glioma cell lines. Cancer Letters. 253(2). 205–214. 11 indexed citations

16.

Rephaeli, Ada, Abraham Nudelman, Nataly Tarasenko, et al.. (2007). Anticancer prodrugs of butyric acid and formaldehyde protect against doxorubicin-induced cardiotoxicity. British Journal of Cancer. 96(11). 1667–1674. 39 indexed citations

17.

Nudelman, Abraham, et al.. (2007). Formaldehyde-releasing prodrugs specifically affect cancer cells by depletion of intracellular glutathione and augmentation of reactive oxygen species. Cancer Chemotherapy and Pharmacology. 62(3). 471–482. 17 indexed citations

18.

Zimra, Yael, et al.. (2000). Uptake of pivaloyloxymethyl butyrate into leukemic cells and its intracellular esterase-catalyzed hydrolysis. Journal of Cancer Research and Clinical Oncology. 126(12). 693–698. 18 indexed citations

19.

Zimra, Yael, Lina Wasserman, Lea Maron, et al.. (1997). Butyric acid and pivaloyloxymethyl butyrate, AN-9, a novel butyric acid derivative, induce apoptosis in HL-60 cells. Journal of Cancer Research and Clinical Oncology. 123(3). 152–160. 30 indexed citations

20.

Rephaeli, Ada, et al.. (1990). Proliferation‐associated changes of Ca²⁺ transport in myeloid leukemic cell lines. Journal of Cellular Physiology. 143(1). 154–159. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact